- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Blue
Recent news which mentions Blue
Why Bluebird Bio's Stock Dived by Over 11% This Week
August 19, 2022
From Motley Fool
From Benzinga
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
August 18, 2022
From Benzinga
Dear AAPL Stock Fans, Mark Your Calendars for Sept. 7
August 18, 2022
From InvestorPlace
BLUE Stock Moves as FDA Approves Bluebird Bio’s Gene Therapy
August 18, 2022
From InvestorPlace
Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
August 18, 2022
From Benzinga
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 18, 2022
From Benzinga
From InvestorPlace
From Benzinga
This contrarian investor gave a timely warning for the last big tech top. He now sees the biggest drop of this bear market dead ahead.
August 18, 2022
From MarketWatch
Cisco, Keysight Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
August 18, 2022
From Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 17, 2022
From Benzinga
Bluebird Secures FDA Nod For Genetic Blood Disease Candidate
August 17, 2022
Tickers
BLUE
From Benzinga
Bluebird's Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive
August 17, 2022
Tickers
BLUE
From Benzinga
From Motley Fool
From Benzinga
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
August 09, 2022
From Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
August 09, 2022
From Benzinga
Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket
August 09, 2022
From Benzinga
From Benzinga
Thomas J. Klima has been named Chief Commercial and Operating Officer of bluebird bio (BLUE). BLUE is trading at $4.71
August 07, 2022
Tickers
BLUE
From Best Stocks
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
August 02, 2022
From Benzinga
Where Will CRISPR Therapeutics Be in 1 Year?
July 31, 2022
From Motley Fool
From Benzinga
Why Legend Biotech's Shares Jumped 11.8% on Wednesday
July 27, 2022
From Motley Fool
Down 35% This Year, Is This Small-Cap Stock a Buy?
July 21, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.